HOGY MEDICAL CO.,LTD.
3593・Prime Market・Textiles & Apparels
Business
HOGY MEDICAL CO., LTD., founded in 1955, is a manufacturer of medical consumables whose core businesses are the manufacture and sale of surgical kit products, medical nonwoven fabric products, and medical devices. Domestically, the company operates manufacturing sites in Miho and Tsukuba, Ibaraki Prefecture, and a distribution center equipped with a fully automated warehouse, while also outsourcing manufacturing to its Indonesian subsidiary (P.T. Hogy Indonesia). Its ASEAN operations are handled by a Singapore subsidiary (Hogy Medical Asia Pacific PTE. LTD.) and an Indonesian sub-subsidiary (P.T. Hogy Medical Sales Indonesia). Its main customers are domestic and overseas medical institutions (hospitals), and its value proposition centers on improving operational efficiency in operating rooms and enhancing medical safety. The company is listed on the Prime Market of the Tokyo Stock Exchange.
Business Model
The company generates revenue by selling to medical institutions "kit products" that package the medical materials needed for surgery by procedure type (particularly the high-value-added "Premium Kit"). It manages costs through contract manufacturing at its Indonesian plant and the expansion of domestically produced in-house components, while deepening relationships with key facilities through system products such as Opera Master. In FY2025 (ended March 2025), net sales were ¥39,138 million, with an operating margin of 9.7%.
Company Strengths
Sales of the top-priority strategic product "Premium Kit" reached ¥13,326 million in FY2025 (ended March 2025), up 17.7% year on year. This accounts for approximately 51% of total Kit Products sales of ¥26,018 million, with sales having grown consistently since launch (August 2016). The product is highly regarded by medical institutions for reducing workload before, during, and after surgery and for ensuring medical safety.
The equity ratio stood at 75.92% at the end of FY2025 (ended March 2025), down from 86.08% in the previous fiscal year but still at a high level, with cash and cash equivalents of ¥21,334 million. This level was maintained even after a large-scale share buyback (2,721,500 shares, resulting in a ¥10,899 million decrease in retained earnings), reflecting strong financial soundness.
The company has built a vertically integrated system combining its domestic Tsukuba and Miho plants (dedicated to kit products and non-woven fabric, respectively), the Tsukuba OPC and other distribution centers equipped with fully automated warehouses, and its Indonesian manufacturing subsidiary. The new Phase II Tsukuba plant began operations in April 2023, and total capital expenditure in FY2025 (ended March 2025) was ¥5,307 million, mainly for the Phase 5 construction work at P.T. Hogy Indonesia.
ENVALITH's Perspective
Performance Trend
Operating profit over the past five fiscal years peaked at ¥6,634 million in FY2023, then declined sharply for two consecutive years to ¥4,169 million in FY2024 and ¥3,810 million in FY2025. The deterioration has continued into the cumulative nine months of FY2026 (ending March 2026), with operating profit of ¥2,088 million (down 38.7% year on year), making a third consecutive year of profit decline all but certain. Revenue also turned negative, falling to ¥28,719 million (down 4.3% year on year). External factors—pressure from medical institutions to reduce material costs and intensifying competition—pushed down sales, while internal factors including upfront increases in SG&A expenses, tender offer-related costs, and rising raw material procurement prices squeezed profits. Operating cash flow fell sharply to ¥1,800 million (versus ¥7,702 million in the same period of the prior year), making the recovery of cash generation capacity a key challenge.
Growth Strategy
Aiming to achieve the medium-term management plan through expanded sales of Premium Kit, overseas expansion, and enhancement of DX products
Promoting the appeal of Premium Kit, the most important strategic product, mainly at key facilities. Cumulative sales for the first three quarters of FY2026 (ending March 2026) reached ¥10,228 million (up 0.6% year on year), the only category to maintain growth amid an overall decline in sales. The company is also focusing on acquiring new customers through proposals to improve operating room utilization rates and reduce workload.
Developing a sales strategy that prioritizes maintaining and strengthening the customer base amid an increasingly competitive environment. As of the end of the third quarter of FY2026 (ending March 2026), the number of Opera Master contracts increased by 8 compared to the end of the previous fiscal year, confirming certain results. The company continues to promote deeper relationships with key facilities.
Actively promoting the introduction of products to major hospitals across ASEAN countries through the Singapore sales subsidiary (HOGY MEDICAL ASIA PACIFIC PTE. LTD.) and the Indonesia sales sub-subsidiary (PT. HOGY MEDICAL SALES INDONESIA). In parallel, the company is also pursuing cost reductions through productivity improvements at its Indonesian manufacturing subsidiary.
Promoting the expansion of DX products and the launch of new components based on the medium-term management plan. Management has noted that progress was largely on schedule as of the third quarter of FY2026 (ending March 2026). This is contributing to an increase in selling, general and administrative expenses, but the company expects it to contribute to earnings over the medium to long term.
Last updated: July 17, 2026